Stephanie Nakano
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 10 | 2026 | 726 | 1.770 |
Why?
| | Cardiomyopathy, Dilated | 5 | 2019 | 340 | 1.430 |
Why?
| | Heart Failure | 10 | 2026 | 2131 | 1.210 |
Why?
| | Cardiomyopathy, Hypertrophic | 7 | 2025 | 144 | 1.170 |
Why?
| | Heart Ventricles | 6 | 2020 | 755 | 1.140 |
Why?
| | Phosphodiesterase 3 Inhibitors | 3 | 2019 | 12 | 1.070 |
Why?
| | Myocardium | 3 | 2017 | 928 | 1.050 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 50 | 1.040 |
Why?
| | Milrinone | 2 | 2021 | 25 | 0.650 |
Why?
| | Troponin I | 1 | 2019 | 72 | 0.590 |
Why?
| | Graft Rejection | 1 | 2022 | 551 | 0.590 |
Why?
| | Myocytes, Cardiac | 3 | 2019 | 546 | 0.570 |
Why?
| | Adenylyl Cyclases | 1 | 2016 | 62 | 0.490 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2016 | 75 | 0.490 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 887 | 0.480 |
Why?
| | Myocardial Contraction | 4 | 2025 | 300 | 0.470 |
Why?
| | Down-Regulation | 2 | 2017 | 644 | 0.470 |
Why?
| | Heart-Lung Transplantation | 2 | 2025 | 13 | 0.470 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 550 | 0.460 |
Why?
| | Calcium | 1 | 2019 | 1183 | 0.400 |
Why?
| | Death, Sudden, Cardiac | 4 | 2023 | 194 | 0.360 |
Why?
| | Lung Transplantation | 2 | 2025 | 325 | 0.360 |
Why?
| | Child | 19 | 2026 | 22725 | 0.360 |
Why?
| | Genetic Therapy | 1 | 2014 | 319 | 0.360 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 722 | 0.350 |
Why?
| | Disease Management | 2 | 2025 | 646 | 0.340 |
Why?
| | Societies, Medical | 2 | 2025 | 873 | 0.340 |
Why?
| | Child, Preschool | 10 | 2023 | 11737 | 0.330 |
Why?
| | RNA | 1 | 2016 | 933 | 0.310 |
Why?
| | Defibrillators, Implantable | 2 | 2023 | 318 | 0.270 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2621 | 0.250 |
Why?
| | Heart-Assist Devices | 2 | 2026 | 572 | 0.250 |
Why?
| | Biomarkers | 1 | 2018 | 4241 | 0.250 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 346 | 0.240 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2026 | 92 | 0.220 |
Why?
| | Sphingosine | 1 | 2025 | 47 | 0.220 |
Why?
| | Lysophospholipids | 1 | 2025 | 75 | 0.220 |
Why?
| | Humans | 27 | 2026 | 143560 | 0.210 |
Why?
| | Mitochondria, Heart | 1 | 2025 | 103 | 0.210 |
Why?
| | Cystic Fibrosis | 1 | 2014 | 1142 | 0.210 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2025 | 140 | 0.210 |
Why?
| | Perfusion | 1 | 2025 | 242 | 0.200 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2023 | 120 | 0.190 |
Why?
| | Electrocardiography | 2 | 2023 | 630 | 0.190 |
Why?
| | Pseudohypoparathyroidism | 1 | 2022 | 3 | 0.190 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 520 | 0.190 |
Why?
| | Cardiomyopathies | 2 | 2026 | 335 | 0.180 |
Why?
| | Male | 15 | 2025 | 71500 | 0.170 |
Why?
| | Infant | 4 | 2023 | 9981 | 0.160 |
Why?
| | Blalock-Taussig Procedure | 1 | 2020 | 5 | 0.160 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 348 | 0.160 |
Why?
| | Heart Bypass, Right | 1 | 2020 | 17 | 0.160 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 43 | 0.160 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 83 | 0.160 |
Why?
| | Ventricular Septum | 1 | 2019 | 8 | 0.150 |
Why?
| | Exercise Test | 1 | 2022 | 624 | 0.150 |
Why?
| | General Practice | 1 | 2019 | 32 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 347 | 0.150 |
Why?
| | Resource Allocation | 1 | 2019 | 53 | 0.150 |
Why?
| | Biopsy | 1 | 2022 | 1083 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.140 |
Why?
| | Adolescent | 9 | 2025 | 22481 | 0.140 |
Why?
| | Educational Status | 1 | 2020 | 464 | 0.140 |
Why?
| | Female | 13 | 2025 | 77251 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1557 | 0.130 |
Why?
| | Calcium-Binding Proteins | 2 | 2016 | 218 | 0.130 |
Why?
| | Phosphorylation | 2 | 2019 | 1781 | 0.130 |
Why?
| | Risk | 1 | 2019 | 906 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 345 | 0.120 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 117 | 0.120 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 270 | 0.120 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 293 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 686 | 0.120 |
Why?
| | Risk Factors | 5 | 2023 | 10644 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2019 | 752 | 0.110 |
Why?
| | Fibrosis | 1 | 2017 | 545 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2019 | 4182 | 0.110 |
Why?
| | Public Health | 1 | 2019 | 565 | 0.110 |
Why?
| | Age Factors | 2 | 2020 | 3328 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 34 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 856 | 0.090 |
Why?
| | Blotting, Western | 1 | 2014 | 1223 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2025 | 11365 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1124 | 0.090 |
Why?
| | Cohort Studies | 4 | 2023 | 5891 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2023 | 6366 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2023 | 16741 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2014 | 783 | 0.070 |
Why?
| | Genomics | 1 | 2014 | 831 | 0.070 |
Why?
| | Young Adult | 4 | 2023 | 13972 | 0.070 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 571 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2020 | 2887 | 0.070 |
Why?
| | Risk Assessment | 3 | 2023 | 3577 | 0.060 |
Why?
| | Echocardiography | 2 | 2019 | 652 | 0.060 |
Why?
| | Prognosis | 1 | 2014 | 4152 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 3041 | 0.060 |
Why?
| | Cyclic AMP | 2 | 2019 | 215 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 389 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2025 | 285 | 0.050 |
Why?
| | Middle Aged | 2 | 2016 | 35342 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 607 | 0.050 |
Why?
| | Chromogranins | 1 | 2022 | 13 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2022 | 9 | 0.050 |
Why?
| | United States | 1 | 2019 | 15553 | 0.050 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 46 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2017 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 95 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 83 | 0.040 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 7 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1671 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 60 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 158 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3625 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 921 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 626 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 882 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1292 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2830 | 0.030 |
Why?
| | Up-Regulation | 1 | 2018 | 863 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 557 | 0.030 |
Why?
| | Aged | 1 | 2014 | 25322 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4522 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 6043 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2531 | 0.020 |
Why?
| | Connexin 43 | 1 | 2012 | 35 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1813 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3380 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 167 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 105 | 0.020 |
Why?
| | Adult | 1 | 2014 | 40013 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2936 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2429 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5308 | 0.020 |
Why?
| | Animals | 2 | 2025 | 38010 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7899 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18378 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5214 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|